This article is for informational purposes only and does not constitute medical advice. Both MadeMed and MEDVi are telehealth platforms — neither provides medical care directly. All medications discussed are compounded and not FDA-approved finished products. Clinical outcomes cited from published trials refer to branded injectable formulations, not compounded products. Consult a qualified healthcare professional before starting any prescription treatment.
I've covered both of these platforms in depth separately — a full MadeMed review and a MEDVi review are both on this site. This piece is specifically for people who have already narrowed the field and are trying to decide between the two.
The short version: they operate in the same market with similar products, but they're not identical. Pricing structure, refund policy, regulatory history, and pharmacy partnerships differ in ways that matter depending on what you're prioritizing.
What They Have in Common
Both MadeMed and MEDVi offer compounded semaglutide and tirzepatide through a telehealth model — online intake, clinician review, compounding pharmacy fulfillment, and home delivery. Both offer injectable and oral (sublingual) formats. Both operate on a cash-pay basis with no insurance billing. Both hold LegitScript certification, which is the primary independent compliance verification used in the telehealth industry. Both disclose in their terms of service that compounded medications are not FDA-approved finished products.
If you're looking for the structural legitimacy signals that distinguish operating-within-the-rules platforms from the sketchier corners of this market, both clear that bar.
Pricing: Where MadeMed Has the Edge
Published entry pricing is where MadeMed is most differentiated. MadeMed's programs start at approximately $99 per month for certain dose levels, with oral sublingual semaglutide cited at approximately $169 per month at starter pricing. The program range runs from $99 to $269 per month depending on medication and dose.
MEDVi's published pricing for compounded injectable semaglutide starts at $179 for the first month, then rises to $299 for refills — a pricing structure that surprises some patients who enrolled expecting the $179 figure to hold. MEDVi's oral semaglutide tablet is listed at approximately $249 per month. Compounded tirzepatide through MEDVi runs higher still.
At starter doses, MadeMed's published pricing is meaningfully lower. At higher doses and on refill cycles, the gap likely narrows — but refill pricing for MadeMed at higher doses was not independently confirmed in public sources and should be verified at mademed.com.
Both platforms offer membership or discount structures that reduce per-month cost. MadeMed has MadeMed Club. MEDVi offers volume-based pricing on longer commitments. Run the math on what you'd actually pay over a 6-month period at refill pricing before deciding that the entry price is the deciding factor.
Regulatory History: MEDVi Has a Warning Letter, MadeMed Does Not (Based on Available Information)
This is the most significant differentiator worth documenting clearly. MEDVi received an FDA warning letter in February 2026. The letter cited misbranding violations — specifically, language on MEDVi's website that falsely implied FDA approval of compounded products and falsely suggested MEDVi was the compounder itself. MEDVi was one of more than 30 telehealth companies warned during a broader enforcement action targeting compounded GLP-1 marketing practices. The letter addressed marketing language, not medication safety or pharmacy quality.
No FDA warning letter specific to MadeMed was identified in public sources reviewed for this article. That doesn't mean one hasn't been issued — the regulatory environment is moving quickly and new enforcement actions are ongoing. Both platforms should be evaluated against their most current public compliance status, not just a snapshot from any single article.
MadeMed's own Terms of Use are notably straightforward about compounding status: they explicitly acknowledge that compounded drugs are not FDA-approved and have not been evaluated for safety or efficacy. That level of upfront disclosure is a positive signal.
Pharmacy Partners
MadeMed's disclosed partner pharmacies are AbsoluteRx and Red Rock Pharmacy. MEDVi has worked with Belmar Pharma Solutions (a 503B outsourcing facility operating since 1985) and Link Compound Pharmacy. Independent research into the specific pharmacy fulfilling your prescription matters more than the platform name — the pharmacy is where quality control actually happens. A 2026 medRxiv preprint identified a novel impurity in compounded tirzepatide combined with vitamin B12, a formulation common among compounding pharmacies. Ask both platforms which specific pharmacy will fulfill your prescription and what quality testing they perform.
Results Guarantee
MEDVi has published a results guarantee: patients who complete five or more months on the program with no weight loss can request a refund. MEDVi reports that 85 percent of patients lose at least 5 percent of body weight within 3 months, according to patient self-reported data — this figure has not been independently verified in a peer-reviewed study. No equivalent results guarantee was confirmed for MadeMed in publicly available information at the time this article was written.
If a results guarantee is important to your decision, MEDVi currently has the edge on this point. Verify current guarantee terms at both platforms before enrolling — these policies can change.
Format Availability
Both platforms offer injectable and oral sublingual formats for semaglutide and tirzepatide. MEDVi has noted this dual-format offering as a specific differentiator in its marketing. MadeMed offers both as well. The clinical caveat applies equally to both: the major weight loss outcomes in peer-reviewed literature — 15 to 17 percent mean body weight loss for injectable branded semaglutide in the STEP trials, and the SURMOUNT-5 head-to-head showing tirzepatide at 20.2 percent versus semaglutide at 13.7 percent — are based on injectable branded medications, not compounded sublingual formulations. Sublingual absorption data for these compounds is not established through the same clinical trial standard.
Who Each Platform Fits Better
MadeMed makes more sense if you're primarily driven by starting cost, want a platform with a clean public regulatory record based on current available information, and are comfortable doing some of your own verification on MadeMed Club membership terms and dose-level pricing before you commit. The $99 entry point is a genuine differentiator if budget is the primary variable.
MEDVi makes more sense if a results guarantee matters to you, if you want a platform with a larger public review volume to evaluate (MEDVi has over 10,000 Trustpilot reviews), or if you specifically want a 503B pharmacy partner. The FDA warning letter is a data point, not a disqualifier — it addressed marketing language, not clinical quality — but it's something to factor into a risk-informed decision.
For the full breakdown of how MadeMed works as a standalone platform — including enrollment steps, subscription terms, and cancellation policy — see the MadeMed pricing and how-it-works guide.
Frequently Asked Questions
Is MadeMed or MEDVi cheaper?
MadeMed's published pricing starts lower — approximately $99 to $169 per month at starter doses depending on format. MEDVi's published starter price for compounded injectable semaglutide is $179 per month for the first month, rising to $299 for refills. For oral sublingual formats, MEDVi's oral semaglutide tablet is listed at approximately $249 per month. MadeMed has the lower published entry price, but pricing at higher doses and refill rates should be verified directly with each platform.
Which has better regulatory standing, MadeMed or MEDVi?
Both MadeMed and MEDVi hold LegitScript certification as of available public information. MEDVi received an FDA warning letter in February 2026 for misbranding violations — the letter addressed marketing practices, not medication safety. No FDA warning letter specific to MadeMed was identified in public sources at the time this was written. Both platforms disclose compounded medication status in their terms of use.
Does MEDVi offer a results guarantee that MadeMed does not?
MEDVi has published a results guarantee — a refund after five or more months with no weight loss based on their patient self-reporting data. No equivalent results guarantee was confirmed for MadeMed in publicly available information at time of writing. Verify current guarantee terms directly with each platform before enrolling.
What is the difference between injectable and oral sublingual GLP-1 medications?
Injectable GLP-1 medications (weekly subcutaneous injection) are the delivery format studied in the major clinical trials that established GLP-1 efficacy — the STEP trials for semaglutide and SURMOUNT-5 for tirzepatide vs semaglutide head-to-head. Oral sublingual compounded formulations have not been evaluated through the same clinical trial standard. Sublingual absorption pharmacokinetics for these compounds are not well established in published literature. Discuss delivery format with a prescribing clinician before choosing.